
The once-daily treatment cut ischemic stroke risk by 26% in a trial, while some patient groups had higher bleeding rates.
The FDA approved Bayer’s Sunharbo on Nov. 9 to reduce the risk of another ischemic stroke in certain adults. In a Phase 3 trial, the drug was linked to a 26% lower risk than placebo.
The trial included 12 thousand 327 people who had recently experienced a mild or moderate ischemic stroke or a high-risk transient ischemic attack. Serious bleeding rates were generally similar, but were higher among patients over 75 and during the first 90 days of treatment. Diarrhea was the most common side effect.
Sunharbo is taken once daily alongside standard treatment to prevent blood clots. As of Tuesday afternoon, Bayer shares traded at 56.78 euros, up 0.28% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.